Clinical trials: SSM
Breast Reconstruction, Implant-Based Breast Reconstruction (IBBR)
Pre- Versus Sub-pectoral Implant-based Breast Reconstruction After Skin-sparing Mastectomy or Nipple-sparing Mastectomy OPBC-02PREPEC
This trial is to investigate whether pre-pectoral Implant-Based Breast Reconstruction (IBBR) provides better Quality of Life (QoL) with respect to long-term (24 months) physical well-being (chest) compared to sub-pectoral IBBR…
- Trial name
- OPBC-02PREPEC (NCT04293146)
- Testing
- pre-pectoral IBBR, sub-pectoral IBBR
- Where
- 22 sites in United States, Austria and 5 more
- Volunteers
- 382 people
- Sponsor
- University Hospital, Basel, Switzerland
Indolent Systemic Mastocytosis
Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis
The objective of this study is to compare the safety and efficacy of masitinib (AB1010) to placebo in patients with mastocytosis with handicap.
- Trial name
- AB06006 (NCT00814073)
- Testing
- Masitinib, Best Supportive Care
- Where
- 24 sites in United States, France
- Volunteers
- 135 people
- Sponsor
- AB Science
HIV Infections
Safety and Tolerability of Z-100 in Patients With Early HIV Infection
The purpose of the study is to see if Z-100 (an investigational drug) treatment is safe in HIV patients who have never received treatment for their HIV, who have not been taking highly active antiretroviral therapy (HAART) for at…
- Trial name
- NCT00016692
- Testing
- Z-100
- Where
- 3 sites in United States
- Sponsor
- Zeria Pharmaceutical
Cervical Cancer
Randomized Study of Z-100 Plus Radiation Therapy to Treat Cervical Cancer
This study is a phase III, multicenter, double-blind, placebo-controlled, parallel group comparative study to evaluate the efficacy and safety of Z-100 with primary uterine cervical cancer on radiotherapy.
- Trial name
- NCT02247232
- Testing
- Z-100
- Where
- 7 sites in Japan, Malaysia and 5 more
- Volunteers
- 793 people
- Sponsor
- Zeria Pharmaceutical
Melanoma (Skin)
Gene Therapy and Ganciclovir in Treating Patients With Stage IV Melanoma
RATIONALE: Inserting a modified herpesvirus gene into a person's melanoma cells may make the cancer more sensitive to the antiviral agent ganciclovir.
- Trial name
- NCT00005057
- Testing
- adenovirus RSV-TK, ganciclovir
- Where
- 3 sites in United States
- Sponsor
- National Human Genome Research Institute (NHGRI)
Indolent Systemic Mastocytosis, Smoldering Systemic Mastocytosis
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
This is a randomized, double-blind, placebo-controlled, Phase 2/3 study comparing the efficacy and safety of elenestinib (BLU-263) + symptom directed therapy (SDT) with placebo + SDT in participants with indolent systemic…
- Trial name
- NCT04910685
- Testing
- Elenestinib
- Where
- 88 sites in United States, Argentina and 23 more
- Volunteers
- 534 people
- Sponsor
- Blueprint Medicines Corporation
Indolent Systemic Mastocytosis
Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment
The purpose of this study is to evaluate the efficacy and safety of oral masitinib versus placebo in the treatment of patients suffering from smouldering or indolent systemic mastocytosis with severe symptoms of mast cell…
- Trial name
- NCT04333108
- Testing
- Masitinib, Best Supportive Care
- Where
- 17 sites in France, Germany and 6 more
- Volunteers
- 140 people
- Sponsor
- AB Science
Non Neoplastic Condition, Precancerous Condition
Thalidomide in Treating Patients With Relapsed or Progressive Systemic Mastocytosis
RATIONALE: Thalidomide may stop the growth of systemic mastocytosis by blocking blood flow to the disease. PURPOSE: This phase II trial is studying how well thalidomide works in treating patients with relapsed or progressive…
- Trial name
- NCT00769587
- Testing
- thalidomide
- Where
- France
- Sponsor
- Centre Hospitalier Universitaire, Amiens
SSM, Mastocytosis, Indolent
(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
This is a multi-part, randomized, double-blind, placebo-controlled Phase 2 clinical study comparing the safety and efficacy of bezuclastinib (CGT9486) plus best supportive care (BSC) with placebo plus BSC in patients with…
- Conditions
- SSM, Mastocytosis, Indolent, Mastocytosis, Systemic, Mastocytosis
- Trial name
- NCT05186753
- Testing
- Bezuclastinib Tablets (Formulation A), Bezuclastinib Tablets (Formulation B)
- Where
- 57 sites in United States, Australia and 13 more
- Volunteers
- 237 people
- Sponsor
- Cogent Biosciences, Inc.
Surgery
SKINI - Radicality of Skin-Sparing and Nipple-Sparing Mastectomy
Prospective collection of health related personal data and biological material (tissue biopsy) in patients undergoing mastectomy.
- Trial name
- SKINI (NCT03470909)
- Testing
- Skin-Sparing Mastectomy (SSM), Nipple-Sparing Mastectomy (NSM)
- Where
- Switzerland
- Volunteers
- 160 people
- Sponsor
- Brust-Zentrum AG
Cervical Cancer
Trial to Optimally Show the Pharmacological Action of Z-100
The objective of this clinical trial is to evaluate the change of the immunological parameter levels in FIGO stage IIIB cervical cancer subjects by administration of Z-100
- Trial name
- NCT03476018
- Testing
- Z-100
- Where
- 2 sites in Vietnam
- Volunteers
- 72 people
- Sponsor
- Zeria Pharmaceutical
Indolent Systemic Mastocytosis
(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis
This is a Phase 2, randomized, double-blind, placebo-controlled study comparing the efficacy and safety of avapritinib + best supportive care (BSC) with placebo + BSC in patients with indolent systemic mastocytosis (ISM) whose…
- Trial name
- NCT03731260
- Testing
- Avapritinib
- Where
- 49 sites in United States, Belgium and 11 more
- Volunteers
- 251 people
- Sponsor
- Blueprint Medicines Corporation
Acral Lentiginous Melanoma, Cutaneous Nodular Melanoma
Dinaciclib in Treating Patients With Stage IV Melanoma
This phase II trial is studying the side effects and how well dinaciclib works in treating patients with stage IV melanoma. Dinaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Acral Lentiginous Melanoma, Cutaneous Nodular Melanoma, Lentigo Maligna Melanoma, Low-CSD Melanoma
- Trial name
- NCT00937937
- Testing
- Dinaciclib
- Where
- 190 sites in United States
- Volunteers
- 72 people
- Sponsor
- National Cancer Institute (NCI)
Acral Lentiginous Malignant Melanoma, Lentigo Maligna Malignant Melanoma
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma
This phase II trial is studying how well gamma-secretase/Notch signalling pathway inhibitor RO4929097 works in treating patients with stage IV melanoma.
- Conditions
- Acral Lentiginous Malignant Melanoma, Lentigo Maligna Malignant Melanoma, Nodular Malignant Melanoma, Recurrent Melanoma
- Trial name
- NCT01120275
- Testing
- gamma-secretase/Notch signalling pathway inhibitor RO4929097, laboratory biomarker analysis
- Where
- 178 sites in United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Mandibular Diseases, SSM
Virtual Anatomical Reconstruction of Mandibular Bone Defects Using a Statistical Shape Model
Hundred already taken CT-scans (50 male and 50 female) will be anonymized. These scans will be segmented and implemented into a statistical shape model that will be used to predict missing hard tissue of a mandible based on the…
- Trial name
- NCT04475237
- Testing
- CT-scan evaluation and segmentation
- Where
- Belgium
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- CADskills
Hepatocellular Carcinoma, Liver Cirrhosis
Liver and Spleen Stiffness to Predict the Presence of Esaphageal Varices in Cirrhotic With Advanced HCC
Elasto-HCC is a prospective, uncontrolled, multicenter observational study involving several hepatology centers in Italy. Patients with liver cirrhosis and advanced hepatocellular carcinoma (HCC) who will need to undergo systemic…
- Conditions
- Hepatocellular Carcinoma, Liver Cirrhosis, Portal Hypertension
- Trial name
- ELASTO-HCC (NCT06773260)
- Testing
- Liver and Spleen stiffness measurement.
- Where
- 12 sites in Italy
- Volunteers
- 150 people
- Sponsor
- Azienda Ospedaliero Universitaria Policlinico Modena
End Stage Liver Disease, Jaundice
SSM Predicts Outcomes of CLD Inpatients With Acute Liver Injury
In this study, a single non-invasive tool, spleen stiffness measurement (SSM), was used to monitor the disease regression of inpatients with chronic liver disease (CLD) and acute liver injury.
- Conditions
- End Stage Liver Disease, Jaundice, Liver Dysfunction, Portal Hypertension
- Trial name
- NCT06173947
- Testing
- FibroScan® Expert 630
- Where
- China
- Volunteers
- 411 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Advanced Chronic Liver Disease
LSM and SSM for the Diagnosis of CSPH: a Prospective Cohort Study
The goal of this observational study is to assess non-invasive tools' efficacy in predicting portal hypertension-related complications in individuals with advanced chronic liver disease.
- Trial name
- NCT06181409
- Where
- Canada
- Volunteers
- 200 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Indolent Systemic Mastocytosis
Midostaurin in Indolent Systemic Mastocytosis
Rationale: Patients with indolent or smoldering systemic mastocytosis can have severe disabling symptoms. Almost all patients have fatigue, a compromised quality of life, hampering normal functioning.
- Trial name
- NCT01920204
- Testing
- Midostaurin,
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- University Medical Center Groningen
Mastocytosis
Mast Cell Connect: A Registry for Patients With Mastocytosis
The Mast Cell Connect Registry is a voluntary, observational database that will capture demographic, socioeconomic, and disease information directly from patients with mastocytosis via a secure web-based tool.
- Trial name
- NCT02620254
- Where
- United States
- Volunteers
- 743 people
- Sponsor
- Blueprint Medicines Corporation